共 50 条
Neoadjuvant treatment strategies for hepatocellular carcinoma
被引:19
作者:
Xu, Lei
[1
]
Chen, Lin
[1
]
Zhang, Wei
[1
]
机构:
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China
来源:
WORLD JOURNAL OF GASTROINTESTINAL SURGERY
|
2021年
/
13卷
/
12期
关键词:
Hepatocellular carcinoma;
Neoadjuvant therapy;
Prognosis;
Indications;
Contraindications;
PORTAL-VEIN EMBOLIZATION;
DRUG-ELUTING BEADS;
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;
GEMCITABINE PLUS OXALIPLATIN;
RECURRENCE-FREE SURVIVAL;
FATTY LIVER-DISEASE;
INFERIOR VENA-CAVA;
TRANSARTERIAL CHEMOEMBOLIZATION;
Y-90;
RADIOEMBOLIZATION;
CONVENTIONAL CHEMOEMBOLIZATION;
D O I:
10.4240/wjgs.v13.i12.1550
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
The incidence of hepatocellular carcinoma (HCC) remains high globally. Surgical treatment is the best treatment for improving the prognosis of patients with HCC. Neoadjuvant therapy plays a key role in preventing tumor progression and even downstaging HCC. The liver transplantation rate and resectability rate have increased for neoadjuvant therapy. Neoadjuvant therapy is effective in different stages of HCC. In this review, we summarized the definition, methods, effects, indications and contraindications of neoadjuvant therapy in HCC, which have significance for guiding treatment.
引用
收藏
页码:1550 / 1566
页数:17
相关论文